Therefore, we validated the performance of the GALR1, TLX1, and ZNF154 markers in independent sets of Illumina 450 K methylation array data available for four cancer types: breast cancer (450 tumors, 149 normal samples), colon cancer (35 tumors, 18 normal samples), lung adenocarcinoma (9 tumors, 11 normal samples), and prostate adenocarcinoma (31 tumors, 16 normal samples). This evidence concerns the gene ZNF154 and prostate adenocarcinoma.